Q4 2024 Earnings Call Transcript March 27, 2025 BioAtla, Inc. beats earnings expectations. Reported EPS is $-0.285, ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Cash and cash equivalents as of December 31, 2024 were $49M , compared to $111.5M as of December 31, 2023. We expect that cost reductions to ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

当PD-1单抗的年销售额突破百亿美元时，全球医药界正把目光投向更艰难的战场——实体瘤细胞治疗。2024年ASCO会议数据显示，全球在研CAR-T项目中针对实体瘤的仅占12.7%，而其中进入临床II期的不足3%。在这个背景下，易慕峰IMC001新增适应症获批的消息犹如一剂强心针：这款靶向EpCAM的CAR-T产品不仅完成中美双报，更将适应症从消化系统肿瘤拓展至泛上皮源性实体瘤，其90%的疾病控制率和 ...

In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...

在临床转化层面，联合治疗策略正在形成新趋势。CAR-T与PD-1抑制剂的序贯使用、与放疗的时空协同，都在打破单一疗法的局限。值得关注的是IMC001临床试验中接受胃切除的病例，这提示免疫治疗可能创造手术机会。这种疗法联用模式，或将重构肿瘤治疗的价值链，使不可切除肿瘤转化为可切除状态，为患者赢得根治机会。

Results of a phase I/II clinical trial of CALEC, limbal epithelial cell grafts generated by an innovative and rigorously standardized manufacturing protocol, showing safety and feasibility for ...

Surgeons restored corneal surfaces in the injured eyes of 14 patients in a small clinical trial. Stem cells from each patient’s healthy eye were cultivated in a lab to grow healthy tissue that could ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript March 6, 2025 CytomX Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.22, expectations were $-0.23.

Revenue: $138.1 million for the full year 2024, up from $101.2 million in 2023. Total Operating Expenses: $113.1 million for 2024, compared to $107.7 million in 2023. R&D Expenses: Increased by $5 ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics Fourth Quarter 2024 Financial Results Call. Please be advised that, today's call is being recorded. I would now ...